Ben Franklin Technology Partners of Southeastern Pennsylvania

MBF Therapeutics, Inc. is a clinical-stage veterinary oncology company dedicated to developing innovative therapies for dogs and cats with cancer. The company's portfolio includes targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing normal healthy cells. Notable products in development include MBFT-101, a combination therapy for sarcomas and lymphoma that merges a polyamine transport inhibitor with a potent enzyme inhibitor, and MBFT-102, an immunotherapy based on the tumor suppressor mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics is exploring gene-based immunotherapeutic vaccines, aiming to revolutionize cancer treatment and infectious disease prevention in companion animals and livestock. The company collaborates with the Lankenau Institute for Medical Research and is headquartered in Ambler, Pennsylvania.

Mitochon Pharmaceuticals, Inc. is a biotechnology company established in 2014 and based in Blue Bell, Pennsylvania. The company is dedicated to developing drugs that target mitochondrial function, aiming to address significant unmet medical needs in treating serious diseases. Its primary focus is on neurodegenerative and neuromuscular disorders, including Huntington's disease, Alzheimer's disease, Parkinson's disease, Duchenne muscular dystrophy, and epilepsy, among others. Mitochon is also exploring potential therapies for metabolic disorders related to over-nutrition, such as diabetes and obesity. The company's research is grounded in the understanding that various diseases are linked to mitochondrial dysfunction, and by correcting these malfunctions, Mitochon seeks to pave the way for innovative disease-modifying therapies. The leadership team comprises experienced industry professionals with a strong commitment to advancing breakthrough drug therapies for conditions with limited treatment options.

Mitochon Pharmaceuticals, Inc. is a biotechnology company established in 2014 and based in Blue Bell, Pennsylvania. The company is dedicated to developing drugs that target mitochondrial function, aiming to address significant unmet medical needs in treating serious diseases. Its primary focus is on neurodegenerative and neuromuscular disorders, including Huntington's disease, Alzheimer's disease, Parkinson's disease, Duchenne muscular dystrophy, and epilepsy, among others. Mitochon is also exploring potential therapies for metabolic disorders related to over-nutrition, such as diabetes and obesity. The company's research is grounded in the understanding that various diseases are linked to mitochondrial dysfunction, and by correcting these malfunctions, Mitochon seeks to pave the way for innovative disease-modifying therapies. The leadership team comprises experienced industry professionals with a strong commitment to advancing breakthrough drug therapies for conditions with limited treatment options.